Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674287 | 0.85 | CYP1A2 (0.44) | POLBRECQLLMNASMN1; SMN2ERN1 | |
| SCHEMBL9820074 | 0.81 | ERN1 (0.43) | POLBRECQLLMNASMN1; SMN2ERN1 | |
| SCHEMBL25272811 | 0.80 | ALDH1A1 (0.36) | POLBRECQLLMNASMN1; SMN2ERN1 | |
| SCHEMBL615179 | 0.79 | POLB (0.32) | POLBRECQLERN1CYP1A2CYP2C9 | |
| SCHEMBL12446383 | 0.78 | RECQL (0.58) | POLBRECQLLMNASMN1; SMN2TDP1 | |
| SCHEMBL6342720 | 0.71 | PKM (0.34) | ERN1 | |
| SCHEMBL10048729 | 0.70 | CYP2C9 (0.36) | POLBERN1TDP1KDM4EALDH1A1 | |
| SCHEMBL19330363 | 0.70 | ERN1 (0.43) | POLBRECQLLMNASMN1; SMN2ERN1 | |
| SCHEMBL19353921 | 0.69 | ERN1 (0.56) | POLBERN1 | |
| SCHEMBL16806287 | 0.68 | IGF1R (0.32) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271153-B2 | Treating diseases associated with hyperglycemia such as diabetes; SGLT2 (sodium/glucose cotransporter 2) inhibitor; 3-(4-Ethylbenzyl)-2-(beta-D-glucopyranosyloxy)-4,6-dimethyl-pyridine for example | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-18 | — | — | US | disclosed |
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-03 | — | — | US | disclosed |
| EP-1405859-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049203-A1 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medical use thereof, and intermediate therefor | GPR119, NPR3, SLC5A2 | POLB 3441/4885RECQL 3534/4885LMNA 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.